UNSPSC 51333402: Batoprazine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EZY3PL8Q0M. European Medicines Agency schedules Batoprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05670MIG. Batoprazine generally arises in the molecular formula C13H14N2O2.

UNSPSC 51333402 Batoprazine is a Commodity code that does not reflect the scope of work actually being procured in recent state and local opportunities. The three most recent solicitations tagged under this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products—none of which are batoprazine. The code shows a fundamental mismatch between its nominal scope and current procurement activity, indicating limited relevant recent purchasing under this specific pharmaceutical commodity.

Issuing bodies soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023); the Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon (response deadline March 26, 2026). Activity is concentrated in the Southeast, South, and Upper Midwest, though the scope of actual procurement—naloxone, generic pharmaceuticals, and OTC products—bears no relationship to batoprazine as a specific drug commodity.